Generic Pharmaceuticals Contract Manufacturing Market (By Drug: By Drug Branded Generics Unbranded Generics By Product API Drug Product By Route of Administration Oral Parenteral Topical Others By Application Oncology Immunology Antidiabetic Neurology Anticoagulants Cardiovascular Respiratory Pain HIV antivirals Others Branded Generics, Unbranded Generics; By Product: API, Drug Product; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Generic Pharmaceuticals Contract Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Generic Pharmaceuticals Contract Manufacturing Market, by Drug, 2024-2034
8.1.1. Branded Generics
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Unbranded Generics
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Generic Pharmaceuticals Contract Manufacturing Market, by Product, 2024-2034
9.1.1. API
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Drug Product
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Generic Pharmaceuticals Contract Manufacturing Market, by Route of Administration, 2024-2034
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Topical
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. Generic Pharmaceuticals Contract Manufacturing Market, by Application, 2024-2034
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Immunology
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Antidiabetic
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Neurology
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Anticoagulants
11.1.5.1. Market Revenue and Forecast (2021-2034)
11.1.6. Cardiovascular
11.1.6.1. Market Revenue and Forecast (2021-2034)
11.1.7. Respiratory
11.1.7.1. Market Revenue and Forecast (2021-2034)
11.1.8. Pain
11.1.8.1. Market Revenue and Forecast (2021-2034)
11.1.9. HIV antivirals
11.1.9.1. Market Revenue and Forecast (2021-2034)
11.1.10. Others
11.1.10.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug (2021-2034)
12.1.2. Market Revenue and Forecast, by Product (2021-2034)
12.1.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.4. Market Revenue and Forecast, by Application (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Product (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Application (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Product (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Application (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug (2021-2034)
12.2.2. Market Revenue and Forecast, by Product (2021-2034)
12.2.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.4. Market Revenue and Forecast, by Application (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Product (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Application (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Product (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Application (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Product (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Application (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Product (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Application (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug (2021-2034)
12.3.2. Market Revenue and Forecast, by Product (2021-2034)
12.3.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.4. Market Revenue and Forecast, by Application (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Product (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Application (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Product (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Application (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Product (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Application (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Product (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Application (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug (2021-2034)
12.4.2. Market Revenue and Forecast, by Product (2021-2034)
12.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.4. Market Revenue and Forecast, by Application (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Product (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Application (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Product (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Application (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Product (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Application (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Product (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Application (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug (2021-2034)
12.5.2. Market Revenue and Forecast, by Product (2021-2034)
12.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.4. Market Revenue and Forecast, by Application (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Product (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Application (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Product (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.1. Metrics Contract Services
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Curia Global, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Centre One
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Syngene International Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Acme Generics Pvt Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Catalent, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Alcami Corp., Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Cambrex Corp.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Aurobindo Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Siegfried Holding AG
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample